VEPTP inhibition with an extracellular domain targeting antibody did not restore albuminuria in a mouse model of diabetic kidney disease
Physiological Reports · 2024
DOI: 10.14814/phy2.70058 ↗At a glance
Journal article in Physiological Reports, 2024. Written by Rajashree Rana and 11 co-authors. Institution: Cardiovascular and Metabolism, Johnson & Johnson Research & Development, Spring House, Pennsylvania, USA. Major MEDLINE topics: Diabetic Nephropathies, Albuminuria, Receptor, TIE-2, Receptor-Like Protein Tyrosine Phosphatases, Class 3. Cited 2 times so far (Crossref); 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: Auris | J&J | Johnson and Johnson Pharmaceutical Research and Development (J&JPRD), Johnson and Johnson Pharmaceutical Research and Development.
Abstract (original language)
Diabetic kidney disease (DKD) is the leading cause of end‐stage kidney disease. DKD is a heterogeneous disease with complex pathophysiology where early endothelial dysfunction is associated with disease progression. The Tie2 receptor and Angiopoietin 1 and 2 ligands are critical for maintaining endothelial cell permeability and integrity. Tie2 signaling is negatively regulated by the endothelial specific transmembrane receptor Vascular Endothelial Protein Tyrosine Phosphatase (VEPTP). Genetic deletion of VEPTP protects from hypertension and diabetes induced renal injury in a mouse model of DKD. Here, we show that VEPTP inhibition with an extracellular domain targeting VEPTP antibody induced Tie2 phosphorylation and improved VEGF‐A induced vascular permeability both in vitro and in vivo. Treatment with the VEPTP blocking antibody decreased the renal expression of endothelial activation markers ( Angpt2 , Edn1 , and Icam1 ) but failed to improve kidney function in db/db uninephrectomized ReninAAV DKD mice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cardiovascular and Metabolism, Johnson & Johnson Research & Development, Spring House, Pennsylvania, USA.
- Cardiovascular and Metabolism, Johnson & Johnson Research & Development, Cambridge, Massachusetts, USA.
- Biologics Discovery, Johnson & Johnson Research & Development, Spring House, Pennsylvania, USA.
ORCID profiles: Rajashree Rana
Funding
- Auris | J&J | Johnson and Johnson Pharmaceutical Research and Development (J&JPRD)
- Johnson and Johnson Pharmaceutical Research and Development
Cite
APA
Rana, R., Natoli, T. A., Khandelwal, P., Pissios, P., Muhammad, A. B., Chipashvili, V., Farrington, K. P., Zhou, W., Zheng, G., Bukanov, N. O., Pocai, A., & Magnone, M. C. (2024). VEPTP inhibition with an extracellular domain targeting antibody did not restore albuminuria in a mouse model of diabetic kidney disease. Physiological Reports. https://doi.org/10.14814/phy2.70058
Vancouver
Rana R, Natoli TA, Khandelwal P, Pissios P, Muhammad AB, Chipashvili V, et al. VEPTP inhibition with an extracellular domain targeting antibody did not restore albuminuria in a mouse model of diabetic kidney disease. Physiological Reports. 2024. doi:10.14814/phy2.70058
BibTeX
@article{Rana2024,
author = {Rana, Rajashree and Natoli, Thomas A and Khandelwal, Puneet and Pissios, Pavlos and Muhammad, Abdul Bari and Chipashvili, Vaja and Farrington, Krista P and Zhou, Wen and Zheng, Gang and Bukanov, Nikolay O and Pocai, Alessandro and Magnone, Maria Chiara},
title = {VEPTP inhibition with an extracellular domain targeting antibody did not restore albuminuria in a mouse model of diabetic kidney disease},
journal = {Physiological Reports},
year = {2024},
doi = {10.14814/phy2.70058}
}
EUVIMED